Cordance Medical is developing a focused ultrasound system that enables precision medicine to brain diseases. We accomplish this by opening the blood-brain barrier (BBB), extending life by accelerating drug approvals, and enabling liquid biopsy (blood) tests to provide a real-time view of the tumor biology. Our platform allows us to open the BBB precisely to physician-directed regions of the brain (e.g., tumor site, amyloid plaque) in a simple, non-invasive 30-minute clinic procedure. Extensive pre-clinical and clinical investigations have demonstrated the safety and efficacy of the focused ultrasound technology at opening the BBB. Cordance has developed a strong IP position enabling a painless, quick, and outpatient product deployment to meet the needs of the community. The company seeks to raise a seed round to fund the company through all pre-clinical activities enabling pivotal human studies next year. Our platform is applicable for glioblastoma (GBM), brain metastasis, Alzheimer's, Parkinson's, epilepsy and mental health.